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Valproate-induced hyperammonemic encephalopathy is an unusual but serious com-
plication that can occur in people with normal liver-associated enzyme levels, and 
despite normal therapeutic doses and serum levels of valproate. Here, we describe 
an adolescent girl suffering from absence seizures, who complained of progressive 
dizziness and general malaise several days after restarting valproate. She developed 
vomiting and decreased consciousness after 3 weeks of valproate use. She had a 
serum ammonia level five times higher than the upper normal limit, normal liver-
associated enzymes, and a supra-therapeutic valproate level. Electroencephalography 
(EEG) showed continuous generalized slowing. Tandem mass spectrometry analysis 
revealed carnitine deficiency. Her consciousness improved after emergent hemodi-
alysis. Her ammonia level and EEG also became normal. Possible mechanisms, risk 
factors and treatments of valproate-induced hyperammonemic encephalopathy are 
described. Physicians should consider this possibility when consciousness disturbance 
occurs in patients treated with valproate.
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Valproate is a branched-chain fatty acid that is 
widely used in therapy for epilepsy. Most of its side 
effects are mild and transient. However, several 
serious adverse effects can occur during valproate 
treatment, such as hepatotoxicity, coagulation dis-
orders, pancreatitis, bone marrow suppression, and 
hyperammonemia. Valproate-induced hyperammo-
nemic encephalopathy (VHE) is a serious disease. 
Valproate occasionally induces stuporous or coma-
tose states associated with an increase in seizure 
frequency and electroencephalography (EEG) changes. 
The encephalopathy is often accompanied by hy-
perammonemia, without signs of hepatic failure.1 
The diagnosis of hyperammonemia is often over-
looked due to an unspecific clinical presentation, 
and normal liver-associated enzyme levels.2 Here 
we describe an adolescent girl who developed hy-
perammonemic encephalopathy after restarting val-
proate monotherapy for absence seizures. Her clinical 
symptoms and hyperammonemia improved rapidly 
after discontinuation of valproate and immediate 
hemodialysis.
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2.  Case Report
A 14-year-old girl had absence seizures controlled 
with regular valproate for 2 years, at a maintenance 
dose of 20−23 mg/kg/day (1000 mg/day). She expe-
rienced no seizure attacks, and the drug level was 
within normal limits during this period. Develop-
mental milestones and school performance were 
normal. However, 4 months before admission, she 
had discontinued the drug by herself. After stopping 
valproate treatment, she had poor appetite with a 
weight loss of about 8 kg within 3 months. She also 
complained of intermittent myoclonic jerks of both 
hands for 2 months before admission. Valproate was 
therefore prescribed again by another doctor, at a 
dose of 25 mg/kg/day (1000 mg/day), 3 weeks be-
fore admission. The patient complained of dizzi-
ness, general malaise and vomiting several days 
after restarting valproate treatment. She denied 
taking any other drugs in the previous 3 months. 
She visited our emergency department because of 
progressively worsening dizziness and general mal-
aise. Physical examination showed a body temper-
ature of 35.7ºC, pulse rate 97/minute, respiratory 
rate 20/minute, and blood pressure 103/72 mmHg. 
Her height was 152 cm (25th−50th percentile) and 
body weight was 42 kg (25th percentile). Her body 
mass index was 18.1 (normal range, 17.6−22.7). 
Neurologic examination was normal. However, she 
gradually became lethargic in the emergency room. 
Laboratory examination revealed an ammonia level 
of 184 μmol/L (normal range, < 33 μmol/L) and val-
proate level of 182 μg/mL (therapeutic range 50−
100 μg/mL). Serum aspartate aminotransferase was 
12 IU/L and alanine aminotransferase 5 IU/L. Blood 
sugar, blood urea nitrogen, creatinine, and electro-
lytes were normal. Blood gas analysis showed pH 
7.455, PCO2 30.3 mmHg, PO2 44.6 mmHg, and HCO3− 
21.2 mEq/L. EEG showed continuous generalized 
slowing (Figure A). Brain computed tomography 
(CT) revealed no significant anomaly. Three hours 
later, the patient became irritable with incoherent 
and dysarthric speech, delusions and asterixis. The 
Glasgow Coma Scale was E4V4M6. Due to suspected 
VHE, we discontinued valproate therapy. Emergent 
hemodialysis was performed once for 3 hours. Her 
consciousness recovered rapidly to normal 12 hours 
after hemodialysis. Her EEG returned to a normal 
rhythm (Figure B), and her serum ammonia decreased 
to 1 μmmol/L, on the following day. The valproate 
level was 24 μg/ml 2 days after hemodialysis. Tandem 
mass spectrometry studies revealed carnitine defi-
ciency (carnitine/acylcarnitine: C0 = 0.58, C2 = 0.52; 
normal range, C0: 1.35−3.18, C2: 1.5−5.56) before 
hemodialysis. After 3 months of follow-up, the pa-
tient had no cognitive impairment or neurologic 
sequelae. Her serum carnitine was normal, free 
carnitine in serum was 5.67 mg/L (normal range, 
4.3−8.5 mg/L), and total carnitine in serum was 
11.09 mg/L (normal range, 6.3−11.6 mg/L). Her anti-
epileptic treatment was changed to lamotrigine due 
to recurrence of absence epilepsy 2 months after 
discharge.
3.  Discussion
The reported incidence of asymptomatic hyperam-
monemia in children with valproate monotherapy 
is 19%.3 However, the incidence of VHE is unknown. 
In contrast to hyperammonemia due to advanced 
liver disease, patients with VHE usually have nor-
mal liver-associated enzyme levels, suggesting a 
mechanism other than hepatic cell injury.4
The clinical manifestations of VHE include an 
acute or subacute decreasing consciousness level 
that progresses from drowsiness to lethargy and 
coma, vomiting, dizziness, and focal neurological 
deficit. Low-grade fever and an increase in seizure 
frequency can also occur. Laboratory tests usually 
show normal liver function with hyperammonemia.5 
VHE can occur in people with normal dose and 
serum levels of valproate.6 The main EEG findings 
are diffuse slowing with a predominance of rhyth-
mical theta and delta activity, as seen in the initial 
EEG in our patient. Triphasic waves can occasionally 
be detected.5 Our patient met all these diagnostic 
criteria.
The pathogenesis of VHE is incompletely under-
stood. Valproate use can induce hyperammonemia 
through several mechanisms. The most important 
route appears to be the inhibition of hepatic mito-
chondrial carbamoylphosphate synthetase-I, the en-
zyme that begins the urea cycle. Hyperammonemia 
has been suggested to be the main cause of enceph-
alopathy.5 It is hypothesized that elevated ammo-
nia levels could have a toxic effect on astrocytes, 
leading to an inhibition of their glutamate uptake 
and to cerebral edema. Extracellular glutamate 
accumulates and can cause excitotoxic neuronal 
injury.1 Excessive ammonia is conjugated in the brain 
with alpha-ketoglutarate to form glutamate, so 
causing alpha-ketoglutarate depletion. Depletion 
of alpha-ketoglutarate in the brain produces a block 
in the Krebs cycle and causes cell damage and neu-
ronal death.7 Some data suggest that VHE may be 
promoted either by a pre-existing carnitine defi-
ciency or by a deficiency induced by valproate 
per se.8 The carnitine deficiency in our patient was 
likely induced by valproate.
The risk factors for valproate-associated hyper-
ammonemia include underlying urea cycle enzyme 
deficiencies, underlying liver disease, long-term 
valproate treatment, concomitant anti-epileptic drug 
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therapy, particularly topiramate, or strict vegetar-
ianism. VHE usually develops within days to weeks 
after initiation of valproate treatment.1 High ini-
tial dose and catabolic state, such as infection, 
trauma or pregnancy, also increase the risk.4,9 Risk 
factors including initiation of treatment, high ini-
tial dose and catabolic state (body weight loss and 
poor oral intake) might have been associated with 
the onset of VHE in our patient.
No relationships between daily dosages and serum 
concentration of valproate, hyperammonemia, and 
the severity of VHE have been demonstrated. In 
one report reviewing 15 VHE patients, the valproate 
level was over the therapeutic level in 40% of pa-
tients, and was within the therapeutic level in the 
other 60% of patients.2 Our patient with VHE had 
a supra-therapeutic valproate level. VHE may be 
evident even in patients who have previously re-
ceived valproate without experiencing any clinical 
or laboratory problems,1,10 as in our patient.
The primary treatment for VHE is the withdrawal 
of valproate. Based on previous studies, complete 
recovery of consciousness generally occurs over a 
period of 2−14 days and the outcome is usually good 
after discontinuation of valproate.3,11 Hydration, 
































Figure (A) Awake electroencephalogram recorded on day 1, before the patient received hemodialysis. It showed 
diffused slow waves, consistent with diffuse cerebral dysfunction. (B) Awake electroencephalogram recorded on day 3, 
after hemodialysis. The slow waves had disappeared, with normal α waves in the posterior head regions. C = central, 
F = frontal, Fp = frontopolar, O = occipital, P = parietal, T = temporal.
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be beneficial.12 L-carnitine might be helpful in the 
prevention, as well as the treatment, of hyper-
ammonemia caused by valproate.4 Hemodialysis is 
a therapeutic option when the ammonia level is 
> 680 μg/dL (400 μmol/L), or when there are sig-
nificant clinical symptoms secondary to hyperam-
monemia progression.13 It is also used in patients 
with toxic valproate levels. Chen et al14 reviewed 
32 patients with toxic valproate levels of whom six 
received hemodialysis. The half-life of valproate 
decreased from 2.2−4.3 hours during hemodialysis. 
They recommended hemodialysis as part of the man-
agement strategy in patients needing to be stabi-
lized and with deteriorating neurologic conditions 
necessitating intubation. In our case, both hyper-
ammonemia and a toxic valproate level were seen, 
with rapid deterioration in the level of conscious-
ness. We regarded this condition to represent a 
progression of “significant clinical symptoms sec-
ondary to hyperammonemia”, and we thus decided 
to perform immediate hemodialysis.
Two cases of VHE have been reported in Taiwan. 
Singh et al15 described a 50-year-old woman taking 
daily carbamazepine for partial epilepsy, who de-
veloped acute confusion after initiation of valpo-
rate add-on treatment for 10 days. The patient had 
a mildly elevated serum ammonia level (81 μg/dL) 
and normal liver function. The serum levels of val-
porate and carbamazepine were 49.1 μg/mL and 
8.6 μg/mL, respectively. This patient developed VHE 
while restarting valporate, with no previous record 
of valporate side effects. The other report described 
a 42-year-old woman who presented with frequent 
seizure attacks and lethargy at an emergency depart-
ment. She had been treated with several anticon-
vulsants, including valproic acid and phenobarbital. 
She also had an elevated serum ammonia level 
(103 μmol/L) and normal liver function. Her val-
proate serum concentration was 85 μg/mL.16 Both 
of these patients recovered after discontinuation 
of valproate.
In conclusion, VHE is a potentially serious com-
plication of valproate treatment. Physicians should 
consider this possibility when consciousness distur-
bance occurs in patients being treated with valproate, 
and should monitor ammonia levels and investigate 
possible risk factors. Early withdrawal of valproate 
is necessary. In our patient, hemodialysis rapidly re-
duced the toxic valproate level and improved her 
level of consciousness and hyperammonemia.
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